Genomic disorders result from copy-number variants (CNVs) or submicroscopic rearrangements of the genome rather than from single nucleotide variants (SNVs). Diverse technologies, including array comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) microarrays, and more recently, whole genome sequencing and whole-exome sequencing, have enabled robust genome-wide unbiased detection of CNVs in affected individuals and in reportedly healthy controls. Sequencing of breakpoint junctions has allowed for elucidation of upstream mechanisms leading to genomic instability and resultant structural variation, whereas studies of the association between CNVs and specific diseases or susceptibility to morbid traits have enhanced our understanding of the downstream effects. In this review, we discuss the hallmarks of genomic disorders as they were defined during the first decade of the field, including genomic instability and the mechanism for rearrangement defined as nonallelic homologous recombination (NAHR); recurrent vs nonrecurrent rearrangements; and gene dosage sensitivity.
Genomic disorders result from copy-number variants (CNVs) or submicroscopic rearrangements of the genome rather than from single nucleotide variants (SNVs). Diverse technologies, including array comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) microarrays, and more recently, whole genome sequencing and whole-exome sequencing, have enabled robust genome-wide unbiased detection of CNVs in affected individuals and in reportedly healthy controls. Sequencing of breakpoint junctions has allowed for elucidation of upstream mechanisms leading to genomic instability and resultant structural variation, whereas studies of the association between CNVs and specific diseases or susceptibility to morbid traits have enhanced our understanding of the downstream effects. In this review, we discuss the hallmarks of genomic disorders as they were defined during the first decade of the field, including genomic instability and the mechanism for rearrangement defined as nonallelic homologous recombination (NAHR); recurrent vs nonrecurrent rearrangements; and gene dosage sensitivity.
Moreover, we highlight the exciting advances of the second decade of this field, including a deeper understanding of genomic instability and the mechanisms underlying complex rearrangements, mechanisms for constitutional and somatic chromosomal rearrangements, structural intra-species polymorphisms and susceptibility to NAHR, the role of CNVs in the context of genome-wide copy number and single nucleotide variation, and the contribution of noncoding CNVs to human disease. described, yet their molecular mechanisms of formation were unclear (Table 1) . By the mid-1990's several genomic disorders were discovered by locus-specific approaches (i.e., Charcot-Marie-Tooth, DiGeorge, Miller-Dieker, Prader-Willi, Smith Magenis syndromes).
However, it was only after sequencing of the human haploid reference genome 2,3 that genome-wide tools became readily available and allowed for unbiased detection of structural variation in a personal genome.
The first decade of the field of genomic disorders (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) solidified key concepts associated with a single copy-number variant (CNV) locus, such as reciprocal microdeletions and microduplications, dosage sensitivity, and mirror traits. 4 The second decade of the field witnessed a further explosion of CNV detection ranging from single exon dropouts to complex rearrangements, allowed for a heightened understanding of recombination based mechanisms as catalysts of CNV formation, and heralded the era of multilocus genomic variation as pertains to genome evolution and disease. Accordingly, in this review, we (1) briefly review the tools for detection and validation of CNVs, (2) elaborate on the inherent instability of the human genome and the upstream mechanisms predisposing to CNV formation, and (3) discuss the downstream mechanisms leading from CNV to clinical manifestations or phenotypic consequences. We highlight the importance of multilocus genomic variation, interplay between CNV and single nucleotide variants (SNVs), and variation involving noncoding regulatory elements.
| CLINICAL SIGNIFICANCE OF CNVS
Copy-number variation, defined as genomic intervals that deviate from the normal diploid state, has been collectively detected in an estimated~12% to 16% of the human genome. 5, 6 It includes both population-specific and individual-specific or "private" variation. [7] [8] [9] An average genome contains 3 to 7 rare variant CNVs. About 5% to 10% of individuals have CNVs larger than 500 kb in size, and 1% to 2% of the population carry CNVs greater than 1 Mb in size. The size of a CNV and its gene density are strongly anti-correlated with its frequency. 6 Since the vast majority of CNVs are unique and nonrecurrent, determining the clinical significance can be challenging. 10, 11 Benign CNVs are often small, intergenic, or encompass genes that can tolerate a change in copy number, whereas pathogenic CNVs are significantly enriched for genes involved in development and genes with constrained evolutionary patterns of duplication and loss. 12 Professional guidelines have been developed for the interpretation and reporting of clinically relevant CNVs, and consider factors such as size (albeit with caution), genomic content, comparison with internal and external databases for population frequency information, and whether the CNV is inherited or de novo. 13 Chromosomal microarray (CMA) has been advocated as a firsttier cytogenetic diagnostic test for patients with unexplained developmental delay/ intellectual disability, autism spectrum disorders, or multiple congenital anomalies. 10 CMA offers a 10% to 20% diagnostic yield in these populations. 10, 14 In addition to CNVs with predictable phenotypic consequences (see Table 2 for examples), rare recurrent CNVs within specific chromosomal regions have been implicated as risk factors for neurodevelopmental diseases. Many of these CNVs have incomplete penetrance and variable expressivity that may be influenced by other genetic, epigenetic and environmental factors. 15 Aside from neurodevelopmental disorders, CNVs have also been
shown to be associated with complex diseases and traits such as
Crohn disease, psoriasis, osteoporosis, body mass index, 9 Alzheimer disease (APP duplication), 16 Parkinson disease (SNCA duplication and triplication), [17] [18] [19] and susceptibility to HIV-1 infection. 20 These may involve common copy-number polymorphisms, often with multiple allelic states defined by variation in copy number and/or genomic structure. 6 CNVs involving genes encoding cytochrome P450 enzymes, such as CYP2D6 which is susceptible to structural variation due to highly homologous pseudogenes, influence drug metabolism and are important in pharmacogenomic screening. 21 
| TOOLS FOR DETECTION OF CNVS

| Chromosomal microarray
Clinical genomics has proven to have both practical implications for patient diagnostics and it has provided new understandings of the genomic underpinnings of disease. 4 Moreover, they do not provide information regarding location of a gained copy in the genome (ie, insertions) nor of its orientation (ie, directly repeated or inverted).
| Whole-exome sequencing
Read depth of next-generation sequencing data can be analyzed in an effort to identify CNVs. Most current available tools for detection of 27 However, current limitations include the inability to clinically interpret much of the observed variation, in particular noncoding variation.
| UPSTREAM MECHANISMS: GENOMIC INSTABILITY PREDISPOSES TO GENOMIC VARIATION
| Recurrent rearrangements
Systematic investigations of structural variation within the human genome, complemented by analysis of rearrangement breakpoint junctions at the nucleotide level, have unveiled the intricacies of the genomic architecture and its inherent instability. 34 Approximately 50% of the human genome consists of repeat sequences, 2 including short segmental duplications and low-copy repeats (LCRs). Segmental duplications are longer than 1 kb and share greater than 90% sequence identity, 35 whereas LCRs consist of clusters of paralogous sequences organized in hierarchal groups of direct and inversely orientated sequence. When positioned within approximately 10 Mb from one another, large LCRs longer than 10 kb and with over~97% sequence identity can predispose to nonallelic homologous recombination (NAHR). 34, 36 Interestingly, duplication of a region significantly predisposes to triplication of that region in subsequent generations. 37 Not surprisingly, genome-wide distribution
patterns of large LCRs demonstrate significant overlap with genomic rearrangements associated with disease ( Figure 1 ). Evidence supports active (hotspots) and inactive (coldspots) crossover intervals. 34, 38 One example of a contributor to genomic instability is the PRDM9 homologous recombination hotspot motif 5 0 -CCNCCNTNNCCNC-3 0 . The concentration of the PRDM9 motif is correlated to the frequency of NAHR at a specific locus, and variation within the protein recognizing this motif can affect frequency of NAHR. 39 
| Nonrecurrent rearrangements
In contrast to recurrent rearrangements, which share breakpoints, genomic content and size in unrelated individuals, nonrecurrent rearrangements are of unique size and genomic content in unrelated individuals ( Figure 1B) . The various rearrangements at a given locus can be aligned in individuals with overlapping phenotypes, to reveal the smallest region of overlap (SRO). Candidate genes within the SRO can then be proposed as the main drivers of the phenotype, whereas genes outside the SRO may modify the phenotype of a particular individual. Alternatively, concomitant dosage perturbation of multiple genes within a SRO may underlie the phenotype. 40 The breakpoint junctions of nonrecurrent rearrangements can be characterized by simple blunt ends or microhomologies, sometimes with small insertions at the breakpoint junction. Polymorphic structural variation in the general population may predispose to complex rearrangements. 41 Implicated molecular mechanisms for such rearrangements differ from NAHR, and include nonhomologous end joining (NHEJ) and replication based mechanisms (RBMs) such as fork stalling and template switching (FoSTeS) and microhomology-mediated break-induced replication (MMBIR). 42, 43 Key to replicative repair is the idea of long distance template switching (TS), 34 and mapping of the breakpoint junctions of the rearrangement products at a nucleotide level is a crucial prerequisite to understanding the DNA "end chemistry" (e.g. single-end, double stranded DNA, seDNA) and for formulating the underlying mechanisms.
| Complex rearrangements
Some CNVs have been shown to be associated with breakpoints of surprising complexity and multiple breakpoint junctions. 44 Complex genomic rearrangements (CGRs) consist of more than 2 breakpoint junctions, such as duplication-inverted triplication-duplication (DUP-TRP/INV-DUP) rearrangements. They can be formed in a single mutational event during DNA repair by iterative template switching within stretches of microhomology. 34, 45 Additionally, CGRs may expand, that is, triplication-normal-triplication pattern to quadruplication-normal-quadruplication pattern. 46 CGRs, in particular triplications, can be associated with extended regions of segmental copy-number-neutral absence of heterozygosity (AOH) or regional uniparental disomy (UPD). Template switches between homologs vs sister chromatids, during repair of double-stranded DNA breaks or during mitotic crossing-over, have been implicated in such rearrangements. 47 Complex exonic, genic and chromosomal rearrangements can be generated in a single mutagenic event by chromothripsis-like events.
Chromothripsis, a chromosome catastrophe involving shattering and subsequent rearrangement of chromosomes in somatic cells, was first recognized in cancers. 48 Chromoanasynthesis describes the analogous phenomenon in constitutional genomic disorders ( Figure 2A ). 49 Recently, a multiple de novo CNV (MdnCNV) phenomenon was described resembling chromosomal instability in cancers, in which individuals with genomic disorders carried 5 to 10 constitutional dnCNVs that originated independently ( Figure 2B ). The active CNV mutation shower, which also included de novo point mutations flanking the rearrangement junctions consistent with replicative repair, appeared to be restricted to a transient perizygotic period. WES performed on selected subjects did not identify specific gene variants that could potentially drive the MdnCNV phenotype, suggesting that the causal mutation resides in an unknown disease gene, noncoding region of a critical gene, or that the driver mutation is lost or suppressed after triggering a CNV mutator phenotype. 50 
| DOWNSTREAM MECHANISMS: FROM CNV TO PHENOTYPE AND BEYOND
CNVs can lead to phenotypes by a variety of pathogenetic mechanisms ( Figures 3 and 4) , including dosage sensitivity of a gene within the CNV; gene interruption or gene fusion at the breakpoint junctions; deletion of a regulatory element; or unmasking of a recessive mutation. 51 Each of these mechanisms will be detailed below. Moreover, we will elaborate on the concepts of CNV mutation burden, noncoding regulatory elements, and the interplay between CNVs and SNVs as related to phenotypic consequences.
| Dosage sensitivity: haploinsufficiency and triplosensitivity
As detailed above, CNVs associated with specific phenotypes can implicate genes within the CNV as potentially causative of those Table 2 ). In other cases, a dosage-sensitive gene has been associated with a specific aspect of a mirror trait-for example, KCTD13 and head circumference size at the 16p11.2 locus (Table 3) . 71 Animal models with reciprocal deletions and duplications can inform dosage-dependent phenotypes associated with a particular CNV. [73] [74] [75] The 16p11.2 CNV mouse models demonstrate dosagedependent changes in gene expression, viability, brain architecture, and behavior, with the deletion being more severe than the duplication. 74 However, caution must be exercised in cases where the data does not accurately reflect the phenotypes seen in humans; modifiers outside the CNV may exist and affect penetrance, expressivity and direction of effects in humans vs mice. 76 Fascinatingly, some neurobehavioral traits are not rescued by restoration of the normal gene copy number in a model compound heterozygous for a deletion and duplication of the same region. 77 Possible explanations include a position effect, modification of the chromatin structure, perturbation of chromatin loops and/or topologically associated domains, disruption of long transcript structure, reflection of a regulatory interaction between chromosome homologs, and/or repositioning within the nucleus of a genomic region.
77-79
FIGURE 3 Downstream mechanisms of monoallelic CNVs. A, Haploinsufficiency due to deletion of a dosage-sensitive gene or triplosensitivity due to duplication of a dosage-sensitive gene leads to phenotypic consequences. Further support of dosage sensitivity comes from triplication of a dosage-sensitive gene associated with a more severe phenotype. B, Deletions may encompass multiple dosage-sensitive genes; in such cases, the overall phenotype can be attributed to the sum of the individual phenotypes or to synergistic effects. C, Gene interruption with subsequent loss of expression can lead to a phenotype. D, Gene fusion within paralogs of a gene family or between gene families can lead to a fusion gene, provided that the reading frame is not disrupted. E, CNVs may disrupt noncoding regulatory elements such as promoters or enhancers, either upstream or downstream of a gene
Defining the dosage-sensitive gene in a particular genomic disorder and understanding the mechanism by which it leads to disease is a prerequisite for seeking therapeutic options. Treatment strategies include regaining correct stoichiometry of the mRNA and encoded protein product, 80 Figure 3C ). 29 CNVs in which genes span both breakpoints can generate fusion genes if the genes are in the same orientation and the reading frame is maintained ( Figure 3D) . 88 This has been well documented for the red-green opsin genes in color blindness, 89, 90 as well as for specific proto-oncogenes in cancer syndromes, where fusion genes are potentially druggable. 91, 92 Moreover, complex rearrangements with inversions can result in novel fusion transcripts that evolve novel genes. 125 
| CNVs involving gene families and pseudogenes
Many genes are members of large families that have arisen through gene duplication events during the course of evolution. 93 and at the ATAD3A-ATAD3B-ATAD3C locus. 96 Alternatively, the high sequence similarity may lead to the transfer of deleterious mutations from the pseudogene to the active gene by a process termed gene conversion (ie, CYP21A to CYP21B), a NAHR driven event. 15, 97 Importantly, pseudogenes have the potential to be harnessed in treatment of severe disease, such as spinal muscular atrophy (SMA)
[MIM 253300].
98,99
| Contribution of CNVs to recessively inherited disease
CNVs contribute to the allelic composition of both carrier and recessive disease-causing mutations, and carrier deletions can encompass multiple recessive disease genes. 100 Biallelic CNVs can cause disease either as homozygous deletions in consanguineous populations 101, 102 or as compound heterozygous deletions 96 ( Figure 4A-B) . Rarely, common DNA rearrangements, each of which independently leads to disease, can aggregate in trans at a single locus 103 or can be seen in homozygous state due to inherited and/or de novo events. Figure 4E ).
| CNVs as part of multilocus variation and mutational burden
It has been documented that approximately 10% of children with intellectual disability and congenital anomalies carry a second large CNV that may contribute to a more severe clinical presentation. 111 As mentioned above, a multiple de novo CNV phenomenon was recently described, in which individuals with genomic disorders carry multiple constitutional CNVs which seem to arise during a specific timeframe during embryonic development. The formation of multiple de novo mutations has no known genetic or environmental trigger as of yet. 50 This "mutation shower" differs from multilocus variation or a mutational burden, wherein both inherited and de novo CNVs and SNVs aggregate within an individual genome and modify phenotypic expression 103 ( Figure 2C ), for instance by biological pathway interactions as exemplified by the ciliopathies [112] [113] [114] and the neuropathies. 115 
| Noncoding regulatory elements and position effect
Topologically associated domains (TADs) are highly conserved genomic segments that partition the genome into large units with frequent intra-domain interactions, and as such are key elements of mammalian regulatory organization. 116 They are separated by topological boundary regions (TBRs), which represent "genomic insulators" by blocking the interactions between adjacent TADs. CNVs in the noncoding regions either upstream or downstream of diseaseassociated genes can lead to disease; deletions, duplications, or inversions may be involved ( Figure 3E Intriguing concepts such as mutation burden, the contribution of noncoding elements to human disease, and the clinical manifestations and potential treatment of specific genomic disorders will surely continue to be a focus of the field in the upcoming decade. 
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